Uploaded February 2026 | Updated November 2026, 3 hours ago
Esta sesión abre el simposio dando la bienvenida a todas las familias, cuidadores y personas diagnosticadas. Se introduce el objetivo central del evento: crear un espacio accesible donde la comunidad hispanohablante pueda aprender, conectarse y encontrar apoyo alrededor de los trastornos neuroinmunes poco frecuentes.
Roberta Pesce | SRNA
Carlos Pardo-Villamizar, MD | Johns Hopkins University, EE. UU.
Esta sesión abre el simposio dando la bienvenida a todas las familias, cuidadores y personas diagnosticadas. Se introduce el objetivo central del evento: crear un espacio accesible donde la comunidad hispanohablante pueda aprender, conectarse y encontrar apoyo alrededor de los trastornos neuroinmunes poco frecuentes.
Roberta Pesce | SRNA
Carlos Pardo-Villamizar, MD | Johns Hopkins University, EE. UU.




![2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Linda Nguyen, MD, PhD, of UT Southwestern Medical Center and Childrens Health, spoke about predicting relapse in children with MOG antibody disease (MOGAD) [00:00:52]. She explained why some children have a single attack while others relapse, the question of starting preventive treatment, and what earlier studies have found [00:01:16]. She described a study across three pediatric centers in the United States, with 225 children identified and 187 followed for at least six months [00:05:42]. Dr. Nguyen reported that 31 percent relapsed, when relapses happened, and which first-attack features mattered, including acute disseminated encephalomyelitis (ADEM) combined with another presentation [00:08:25]. She showed that repeat MOG antibody tests months after the first attack were the strongest clue, with negative or low results reassuring and higher titers linked to more relapses [00:15:00].
Linda Nguyen, MD, PhD, is an Assistant Professor of Pediatrics at UT Southwestern Medical Center and Childrens Health in Dallas, Texas. She completed her MD and PhD training at West Virginia University in 2017, a pediatric neurology residency at UC San Diego in 2022, and a neuroimmunology fellowship at UT Southwestern.
00:00 Introduction
00:52 Predicting Relapse in Children
01:16 What the Talk Will Cover
02:48 What Earlier Studies Found
05:42 What This Study Adds
06:51 The Two Research Questions
08:25 How Many Children Relapsed
09:55 First-Attack Clues
15:00 Antibody Tests Over Time
17:34 Key Takeaways
18:33 Limits and Next Steps 2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse](https://i.ytimg.com/vi/9vxLdj0IAVI/mqdefault.jpg)

![1311. Understanding Myelitis: Efforts to Update Diagnostic Criteria
In this episode of the SRNA Ask the Expert podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from transverse myelitis to myelitis will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].
Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis.
Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.
Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children’s Medical Center.
Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago’s Rush Presbyterian-St. Luke’s Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor’s degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation’s first dedicated Transverse Myelitis Center.
Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
00:00 Introduction
00:58 Overview of Myelitis and Diagnostic Criteria
02:57 Historical Context and Importance of Updated Criteria
05:10 Challenges with Current Terminology
11:10 Changes in Understanding and Diagnostic Approaches
17:27 Implications for Patients and Clinical Practice
23:40 Impact on Research and Future Directions
28:58 Patient Advocacy and Resources
31:17 Conclusion and Final Thoughts 1311. Understanding Myelitis: Efforts to Update Diagnostic Criteria](https://i.ytimg.com/vi/AisPcfLkAz8/mqdefault.jpg)

![Ask the Expert 1401. Open Q&A on Neuromyelitis Optica Spectrum Disorder (NMOSD)
In SRNA’s Ask the Expert episode moderated by Krissy Dilger, Dr. Elena Grebenciucova described neuromyelitis optica spectrum disorder (NMOSD) symptoms including optic neuritis, transverse myelitis, brainstem syndromes, and intractable hiccups [00:01:05]. She outlined diagnostic evaluation using MRI and correct blood-based antibody testing (preferably cell-based assays), common diagnostic pitfalls, and the need to rule out infections before immunosuppressive treatment [07:08]. Dr. Grebenciucova reviewed urgent relapse management with IV steroids and early plasma exchange, side effects, long-term preventive therapies (FDA-approved and off-label) [14:02]. Finally, she answered community questions on supplements, chronic optic neuritis, rehab appeals, pain/spasticity, pregnancy planning, long-term treatment duration, mental health, seronegative syndromes, follow-up frequency, and recovery expectations [25:22].
Elena Grebenciucova, MD completed neurology residency at the University of Chicago in Chicago, Illinois. Dr. Grebenciucova has been interested in autoimmune disorders of the central nervous system, including rare neuroimmune disorders, since medical school. After residency, she completed a neuroimmunology Fellowship under the mentorship of Dr. Brenda Banwell and Joseph Berger at the Perelman School of Medicine of The University of Pennsylvania. Currently she is an assistant professor of Neurology (MS/Neuroimmunology) and neurological infections at Northwestern University in Chicago, Illinois, and she runs the Transverse Myelitis Center there. Dr Grebenciucova sees patients with rare autoimmune conditions including NMOSD, MOGAD, transverse myelitis, and autoimmune encephalitis.
00:00 Welcome and Introduction
01:05 What Is NMOSD?
01:59 Symptoms and Relapse Signs
03:27 What Causes NMOSD?
07:08 How NMOSD Is Diagnosed
10:09 Key Tests and Pitfalls
14:02 Acute Attack Treatment
17:18 Steroid Side Effects
22:19 Long-Term Therapies Worldwide
25:22 Community Questions, Beginning with Vitamins
27:40 Optic Neuritis Breakthroughs
28:47 Chronic Optic Nerve Inflammation
29:19 Winning Insurance Appeals
31:23 Waist Band Pain and Spasticity
34:04 Pregnancy and Family Planning
37:40 Stopping Long-Term Treatment
39:40 Long-Term Side Effects
43:04 Mood and Personality Changes
49:47 Trials for Seronegative NMOSD
52:55 Follow Up Visit Schedule
55:34 Relapse Recovery Timeline
58:02 Closing Ask the Expert 1401. Open Q&A on Neuromyelitis Optica Spectrum Disorder (NMOSD)](https://i.ytimg.com/vi/BrGUWR9fefM/mqdefault.jpg)

![2026 RNDS | State of the Science Across Rare Neuroimmune Disorders and Clinical Trials Panel
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital and Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern talked through the state of the science across rare neuroimmune disorders and clinical trials [00:00:05]. They started with epidemiology maps, what they can show about possible genetic hotspots, and why a place with no dots may simply lack access to antibody testing [00:00:57]. They discussed how genetics, environment, and timing may combine to cause these disorders [00:05:15], then how immune activity outside the nervous system may move in and out of it [00:07:48]. They explained why antibodies are more complicated than a single positive test, and how an antibody can be present during remission [00:10:46]. They covered MRI, blood tests, false negatives, and spinal fluid testing [00:20:24], and closed with MOGAD trials, insurance case managers, future therapies, and audience questions [00:31:38].
Benjamin Greenberg, MD, MHS, is Director of the Perot Foundation Neurosciences Translational Research Center within the ODonnell Brain Institute and Vice Chair of Translational Research for the Department of Neurology at University of Texas Southwestern Medical Center. He directs the Transverse Myelitis and Neuromyelitis Optica Program and established the Pediatric Demyelinating Disease Program at Childrens Medical Center Dallas in 2009. He is recognized internationally as an expert in rare autoimmune disorders of the central nervous system.
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Welcome and Panel Introductions
00:57 Epidemiology and Global Maps
05:15 Genetics, Environment, and Timing
07:48 How These Disorders Develop
10:46 Why Antibodies Are Complicated
16:25 Antibodies and Remission
20:24 MRI in Daily Care
24:39 Blood Tests and Antibody Assays
29:44 Spinal Fluid Testing
31:38 Clinical Trials Overview
33:58 Trials and Treatment Decisions
39:44 Insurance Case Managers
41:12 Future Therapies
42:54 Audience Questions and Closing 2026 RNDS | State of the Science Across Rare Neuroimmune Disorders and Clinical Trials Panel](https://i.ytimg.com/vi/CGXa2UX81l8/mqdefault.jpg)